GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival In P [Archive]

View Full Version : GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival In P

News

12-12-2009, 05:02 AM

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab)...

More... (http://www.medicalnewstoday.com/articles/173837.php)